Phil Nadeau
Stock Analyst at TD Cowen
(3.97)
# 1,827
Out of 5,118 analysts
800
Total ratings
47%
Success rate
4.4%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Reiterated: Buy | $12 | $12.21 | -3.60% | 22 | Nov 5, 2026 | |
| ANNX Annexon | Reiterated: Buy | $3.94 | $4.20 | -6.19% | 20 | Nov 4, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $120 | $56.03 | +114.17% | 87 | Nov 3, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $220 | $164.63 | +33.63% | 58 | Nov 3, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $130 | $112.28 | +15.78% | 38 | Nov 3, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $550 → $575 | $547.09 | +5.10% | 89 | Nov 3, 2026 | |
| BIIB Biogen | Reiterated: Buy | $250 → $260 | $248.35 | +4.69% | 57 | Oct 29, 2026 | |
| SRZN Surrozen | Reiterated: Buy | n/a | $31.00 | - | 3 | Oct 12, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | n/a | $49.43 | - | 19 | Oct 7, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Buy | n/a | $11.53 | - | 21 | Oct 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.31 | - | 1 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.30 | - | 16 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.68 | - | 5 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.27 | - | 22 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.73 | - | 2 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.87 | - | 43 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.57 | - | 28 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.54 | - | 22 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.56 | - | 13 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.54 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.87 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0004 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $33.45 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.50 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.75 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $75 | $166.89 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.25 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.04 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $2.39 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $904.35 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.39 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $16 | $0.000001 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $460.42 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.78 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $562.02 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.82 | n/a | 1 | Aug 7, 2015 |
Vir Biotechnology
Nov 5, 2026
Reiterated: Buy
Price Target: $12
Current: $12.21
Upside: -3.60%
Annexon
Nov 4, 2026
Reiterated: Buy
Price Target: $3.94
Current: $4.20
Upside: -6.19%
BioMarin Pharmaceutical
Nov 3, 2026
Reiterated: Buy
Price Target: $120
Current: $56.03
Upside: +114.17%
Neurocrine Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $220
Current: $164.63
Upside: +33.63%
Rhythm Pharmaceuticals
Nov 3, 2026
Reiterated: Buy
Price Target: $130
Current: $112.28
Upside: +15.78%
Vertex Pharmaceuticals
Nov 3, 2026
Reiterated: Buy
Price Target: $550 → $575
Current: $547.09
Upside: +5.10%
Biogen
Oct 29, 2026
Reiterated: Buy
Price Target: $250 → $260
Current: $248.35
Upside: +4.69%
Surrozen
Oct 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $31.00
Upside: -
Enliven Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $49.43
Upside: -
MoonLake Immunotherapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.53
Upside: -
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.31
Upside: -
Sep 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.30
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.68
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.27
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.73
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.87
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.57
Upside: -
Aug 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.54
Upside: -
May 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.56
Upside: -
Apr 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.54
Upside: -
Mar 9, 2025
Reiterated: Buy
Price Target: n/a
Current: $7.87
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0004
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: n/a
Current: $33.45
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $3.50
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $14.75
Upside: n/a
Feb 4, 2021
Reiterated: Buy
Price Target: $80 → $75
Current: $166.89
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $9.25
Upside: n/a
Aug 7, 2019
Reiterated: Buy
Price Target: n/a
Current: $1.04
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $2.39
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $904.35
Upside: n/a
Jan 17, 2019
Reiterated: Hold
Price Target: n/a
Current: $2.39
Upside: n/a
Nov 2, 2018
Reiterated: Buy
Price Target: $2 → $16
Current: $0.000001
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $460.42
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $1.78
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $562.02
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $17.82
Upside: n/a